All In Biotech

Drug Trial Radar · NCT06614816

Immunogenicity and Safety of a Live Attenuated Varicella Vaccine in Children Aged 1-12 Years

Phase III Clinical Trial of Lyophilized Live Attenuated Varicella Vaccine for Children Aged 1-12 Years

Last checked: Nov 20, 2026Latest source record: Sep 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,200 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,200

Actual

Start

Feb 10, 2019

Primary completion

Jul 15, 2021

Study completion Jun 20, 2022

Sponsor

Lead sponsor
Southeast University, ChinaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Jiangsu CDC
First posted
Sep 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 1 year, up to 12 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Immunogenicity and Safety of a Live Attenuated Varicella Vaccine in Children Aged 1-12 Years: A Phase III, Randomized, Double-Blind, Active-Controlled Study

Conditions

  • Chickenpox Vaccines

Interventions

  • Oka strain varicella attenuated live vaccineBiological

    lyophilized powder, subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. seroconversion rateTime frame: 42 days after completing the full course of vaccination.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Huaiyin District Center for Disease Control and Prevention

    Huaian, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.